<DOC>
	<DOCNO>NCT02797769</DOCNO>
	<brief_summary>This retrospective cohort study analyze data multiple large U.S. health insurance claim database compare use tocilizumab biologic disease-modifying anti-rheumatic drug ( DMARDs ) real world patient RA . Using date dispense index date , analysis compute time first event several cardiovascular outcome .</brief_summary>
	<brief_title>A Time Cardiovascular Event Analysis Comparing Tocilizumab Other Biologics Patients With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>At least 1 inpatient 2 outpatient diagnosis RA Continuous medical/pharmacy coverage full claim data available At least 6 month insurance plan enrollment prior index date Nursing home resident Human immunodeficiency virus ( HIV ) Malignancy Receipt chemotherapy Endstage renal disease , dialysis , transplant Use rituximab Recent cardiovascular event ( include MI , stroke , ACS , HF ) within 90 day prior index date</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>